DCTH - Delcath Systems, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
2.13
+0.33 (+18.33%)
At close: 3:51PM EDT
Stock chart is not supported by your current browser
Previous Close1.80
Open1.88
Bid0.00 x 0
Ask0.00 x 0
Day's Range1.88 - 2.20
52 Week Range1.76 - 27,125.00
Volume9,858
Avg. Volume9,352
Market Cap1.985M
Beta-0.95
PE Ratio (TTM)N/A
EPS (TTM)-79.64
Earnings DateMar 23, 2017 - Mar 24, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est16.00
Trade prices are not sourced from all markets
  • GlobeNewswire12 hours ago

    Delcath Announces Beginning of Enrollment of Amended Metastatic Ocular Melanoma Registration Trial

    Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that patient enrollment has begun under the amended protocol for its registration trial in ocular melanoma liver metastases. Stanford University Medical Center is the first trial site to obtain Institutional Review Board (IRB) approval for the amended protocol and the center is open to patient enrollment.

  • GlobeNewswire3 days ago

    Delcath Issues Letter to Stockholders

    Delcath Systems, Inc. (DCTH) (“Delcath” or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that Jennifer K. Simpson, Ph.D., MSN, CRNP, President and Chief Executive Officer, has issued a Letter to Stockholders providing a business update. The full text of the Letter, which has also been posted to the Company's website, is as follows. The steps we announced recently are the result of many months of behind the scenes work with the FDA and are intended to significantly reduce the time to submission of a New Drug Application (NDA) in the ocular melanoma indication, to provide this critical therapy to patients in a more timely manner and to fully realize the commercial potential of our PHP® Therapy.  I write to you today to discuss what these steps mean for our shared future and why we believe they can lead to shareholder value.

  • GlobeNewswire5 days ago

    Delcath Announces Second Quarter Fiscal 2018 Financial Results

    NEW YORK, Aug. 15, 2018-- Delcath Systems, Inc., an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces financial results for the quarter ended June ...

  • GlobeNewswire14 days ago

    Delcath Announces Commencement of Rights Offering Subscription Period

    Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces the subscription period for its previously announced rights offering begins on Tuesday, August 7, 2018 (upon declaration of effectiveness of its registration statement on Form S-1 by the SEC). Under the terms of the rights offering, Delcath distributed, at no charge, non-transferable subscription rights to purchase 500 shares of its common stock to holders of record for each share of common stock held on the record date, and to holders of its warrants to purchase common stock. Each basic subscription right will entitle the holder of record to purchase 500 shares of common stock at the subscription price of $1.75 per share.

  • GlobeNewswire20 days ago

    Summary of Calendar for Upcoming Proposed Delcath Rights Offering

    Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, reminds investors that the ownership date cutoff for the Company’s upcoming rights offering is August 1, 2018 at 4 P.M. Eastern Time.  The Company previously filed a registration statement with the SEC for the sale of up to 28,571,429 shares of common stock at a subscription price of $1.75 per share. The offering will only be made upon the registration statement being declared effective by the SEC.  The rights offering would also allow the Company’s Board of Directors, officers and employees to participate on the same terms as other shareholders in the Company, and the entire board and members of the Company’s management team have indicated an intent to participate.

  • GlobeNewswire24 days ago

    Delcath Amends Phase 3 Ocular Melanoma Trial Protocol

    NEW YORK, July 27, 2018 (GLOBE NEWSWIRE) --  Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company has filed an amendment with the U.S. Food & Drug Administration to revise the protocol for its Phase 3 clinical trial in ocular melanoma liver metastases. Under the terms of the amendment, the trial, now entitled, A Single-arm, Multi-Center, Open-Label Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients with Hepatic-Dominant Ocular Melanoma, will enroll 80 patients with ocular melanoma metastatic to the liver.

  • GlobeNewswirelast month

    Delcath Systems Announces Rights Offering and Backstop Commitment Ownership Date of August 1, 2018

    Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that it has filed a registration statement on Form S-1 with the SEC for a rights offering for up to 28,571,429 shares of common stock at the subscription price of $1.75 per share. Under the terms of the rights offering, on August 3, 2018, Delcath expects to distribute, at no charge, 500 non-transferable subscription rights to purchase shares of its common stock to holders of record for each share of common stock held on the record date, and to holders of its warrants to purchase common stock held on the Ownership Date, as of 4:00 p.m., Eastern time, on Wednesday, August 1, 2018.

  • GlobeNewswirelast month

    Delcath Announces 100th Commercial CHEMOSAT Treatment Completed at Leiden University Medical Center, The Netherlands

    Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that physicians at Leiden University Medical Center (LUMC) in the Netherlands, led by Dr. Mark C. Burgmans, completed their 100th treatment with PHP® Therapy using the company’s Hepatic CHEMOSAT® Delivery System (CHEMOSAT). Percutaneous Hepatic Perfusion (PHP) Therapy with Melphalan/HDS was developed by Delcath Systems as a targeted, whole organ therapy for the liver.

  • GlobeNewswire3 months ago

    Delcath Systems to Present at the 8th Annual LD Micro Invitational

    Delcath Systems, Inc. (DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that it will be presenting at the 8th Annual LD Micro Invitational on Monday, June 4 at 12:00pm PST / 3:00pm EST. Jennifer K. Simpson, PhD, MSN, CRNP, President and Chief Executive Officer of Delcath Systems, will be presenting and meeting with investors. Dr. Simpson’s presentation will be webcast live on the internet and can be accessed by visiting the News and Events section of the Company’s website at www.delcath.com.

  • OTCQX And OTCQB Companies to Present At 2018 ROTH Conference
    PR Newswire5 months ago

    OTCQX And OTCQB Companies to Present At 2018 ROTH Conference

    OTC Markets Group EVP Jason Paltrowitz to Speak on Panel on "Reg A+ Offerings" NEW YORK , March 8, 2018 /PRNewswire/ -- OTC Markets Group Inc.  (OTCQX: OTCM), operator of financial markets for ...